Back to Treatments

Treatment

Empagliflozin (SGLT2 Inhibitor)

1
Conditions
69
Trials
80K
Participants
60%
Average Safety

Condition Evidence

Diabetes mellitus type 2

69 trials · 80K participants

89% effectiveness · 60% safety
Empagliflozin (SGLT2 Inhibitor) | DFDA